/ WHO WE ARE
RiverVest is a leading venture capital firm building life science companies to address significant unmet medical needs.
8
FUNDS
Since 2000
/ CASE STUDY
Good Therapeutics, founded in 2016 by John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained its platform and the ability to mine it for innovative drugs to fight cancer and other diseases.
/ EXPERT INSIGHT
RiverVest’s latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease.
/ CASE STUDY
RiverVest led the Series A investment in Standard Bariatrics in 2018. The surgical device company was acquired by Teleflex, Inc. in 2022 for $170 million plus additional milestone payments.
28
COMMERCIAL PRODUCTS
Currently Treating Patients
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.
Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2023 RiverVest® All Rights Reserved. | Privacy Policy
Subscribe to our newsletter